| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03173963 Details | 2020-02-25 Interventional | 3 | 0 | Empagliflozin Diabetes Mellit… Diabetic Nephro… Kidney Diseases Diabetes Mellit… Diabetic Kidney… | Original drug sponsor withdrew from study, replacement sponsor not obtained. - | |||
| NCT03035578 Details | 2020-02-25 Interventional | 1/2 | 0 | Morphine Drug Effect Pain | research project has been abandoned primarily because of the excessive delays associated with
past challenges in obtaining approval from Health Canada - | |||
| NCT02541604 2014-004697-41 Details | 2020-02-25 Interventional | 1/2 | 87 | Atezolizumab Neoplasms Solid Tumor | Sponsor decision to terminate because limited investigational agent activity was observed. - | |||
| NCT01749293 Details | 2020-02-25 Interventional | 2 | 3 | Busulfan Cyclophosphamid… Fludarabine Hematologic Neo… Neoplasms Hematologic Mal… | The protocol design is being reconfigured in order to open a new study. - | |||
| NCT02066311 Details | 2020-02-24 Interventional | 2 | 15 | Nelfinavir Lupus Erythemat… Systemic Lupus … | Stage 1 terminated 6/1/18 prior to completion of Stage 1 due to low enrollment and efficacy - | |||
| NCT01629511 Details | 2020-02-24 Interventional | 1/2 | 15 | Antilymphocyte … Busulfan Clofarabine Gemcitabine Lenograstim Methotrexate Tacrolimus Thymoglobulin Leukemia Leukemia, Lymph… Leukemia, Lymph… Leukemia, Proly… Allogeneic Hema… Chronic Lymphoc… Prolymphocytic … Richter Syndrom… | - Early termination leading to small number of subjects analyzed. This study never moved to Phase II, therefore was not analyzed. | |||
| NCT04279938 Details | 2020-02-21 Interventional | 1 | 0 | Pembrolizumab Rituximab Lymphoma, Large… Relapsed or Ref… | Safety data on drug - | |||
| NCT02134067 Details | 2020-02-21 Interventional | 1 | 30 | Paclitaxel TAS-119 Neoplasms Advanced Solid … | - - | |||
| NCT02448589 2014-001272-63 Details | 2020-02-20 Interventional | 1 | 74 | TAS-119 Advanced Solid … | - - | |||
| NCT02134912 Details | 2020-02-20 Interventional | 2 | 1 | Crizotinib Pemetrexed Tyrosine Kinase… Adenocarcinoma … Carcinoma, Non-… Lung Neoplasms Adenocarcinoma … Large Cell Lung… Recurrent Non-s… Stage IV Non-sm… | science has moved forward and there is no intent to complete the study The one patient that enrolled immediately withdrew consent [enrolled the day before the study closed]. No manuscript will be forthcoming. | |||
| NCT00544700 Details | 2020-02-20 Interventional | 3 | 265 | Bevacizumab Colorectal Neop… Colorectal Canc… | Data collection is completed. As no changes in the endpoints were expected in the future, no
further data is needed. - | |||
| NCT04158700 2019-001156-18 Details | 2020-02-19 Interventional | 1/2 | 0 | Pembrolizumab Neoplasms Advanced Cancer | The withdrawal is due to a strategic realignment and is not related to any particular safety or
efficacy concern. - | |||
| NCT04220281 Details | 2020-02-17 Interventional | 1/2 | 40 | Nitroglycerin Propofol Hypotension Hypotensive Ane… | the number of patients needed for the study have been collected - | |||
| NCT03982121 2017-005020-14 Details | 2020-02-17 Interventional | 1 | 0 | Ipilimumab Nivolumab Colorectal Neop… Colorectal Canc… | Study never began because of withdrawal of the industrial partner - | |||
| NCT02596555 Details | 2020-02-17 Interventional | 4 | 400 | Dabigatran Embolism Pulmonary Embol… | 1. Interim results suggested a reduction of sample size.
2. Anticipated length of enrolment period with resulting funding issues to pose a threat to
the study. - | |||
| NCT02208063 Details | 2020-02-17 Interventional | 3 | 121 | Cefazolin Cloxacillin Daptomycin Nafcillin Oxacillin Penicillins Telavancin Vancomycin Bacteremia | Halted due to lack of statistical power. No safety concerns identified. At the interim analysis, study was deemed to be inadequately powered & terminated prematurely. | |||
| NCT01671488 Details | 2020-02-17 Interventional | 1/2 | 11 | Mitomycin Mitomycins Anus Neoplasms Anal Cancer | pilot data to be used for upcoming larger trial. - | |||
| NCT01669720 Details | 2020-02-17 Interventional | 2 | 10 | Aflibercept Colorectal Neop… Metastatic Colo… | Lack of efficacy and enrollment - | |||
| NCT01057277 Details | 2020-02-17 Interventional | 1 | 3 | Everolimus Head and Neck N… Head and Neck C… | Pharmaceutical co- re aligned their specialties- no longer will fund H&N ca - | |||
| NCT02771925 Details | 2020-02-13 Interventional | 4 | [5 Refs] | 25 | Gabapentin Alcoholism Alcohol Depende… | Due to poor compliance of patients in the study. - |